RALMITARONT
Ralmitaront is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target trace amine-associated receptor 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
4 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | 2 | — | — | — | 3 |
| Psychotic disorders | D011618 | — | F20.81 | — | 2 | — | — | — | 2 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | RALMITARONT |
| INN | ralmitaront |
| Description | Ralmitaront (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names RG-7906 and RO-6889450) is an investigational antipsychotic drug which is undergoing a clinical trial for the treatment negative symptoms in schizophrenia and schizoaffective disorder. Another clinical trial targeting acute psychotic symptoms of schizophrenia has been terminated due to lack of efficacy. It is a partial agonist of the TAAR1. The medication is being developed by the pharmaceutical company Hoffmann-La Roche. Ralmitaront had completed phase 1 clinical trials.
|
| Classification | Small molecule |
| Drug class | trace amine associated receptor (TAAR) agonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCc1[nH]nc(C(=O)Nc2ccc([C@H]3CNCCO3)cc2)c1C |
Identifiers
| PDB | — |
| CAS-ID | 2133417-13-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4594376 |
| ChEBI ID | — |
| PubChem CID | 130429734 |
| DrugBank | — |
| UNII ID | QA8MW1Q80P (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 43 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use